重药控股：药友制药已收到辉瑞支付的首付款15000万美元

Core Viewpoint - The collaboration between Zhenyao Holdings' subsidiary, Yaoyou Pharmaceutical, and Pfizer, along with Shanghai Fosun Pharmaceutical, marks a significant step in the development and commercialization of GLP-1R agonists, indicating potential growth in the pharmaceutical market [1] Group 1 - Zhenyao Holdings announced a collaboration agreement with Pfizer and Shanghai Fosun Pharmaceutical on December 9, 2025 [1] - The agreement grants Pfizer exclusive rights to develop, use, produce, and commercialize GLP-1R agonists, including YP05002, across global markets and for all human and animal indications [1] - Yaoyou Pharmaceutical has received an initial payment of $15 million from Pfizer as part of this collaboration [1]